1. 疾病领域
  2. 癌症 血液和心血管疾病
  3. 白血病/淋巴瘤/骨髓瘤 血液疾病
  4. 白血病/淋巴瘤/骨髓瘤
  5. 急性淋巴细胞白血病

Acute Lymphoblastic Leukemia  (急性淋巴细胞白血病)

急性淋巴细胞白血病 (ALL) 是一种侵袭性血液系统恶性肿瘤,其特征是骨髓和外周血中未成熟淋巴细胞(淋巴母细胞)快速增殖,导致正常造血功能受到抑制。该病主要影响儿童,但也可发生在成人,且年轻人发病率更高。该病导致异常淋巴细胞不受控制地生长,这些淋巴细胞会渗入骨髓、外周血,并常扩散至淋巴结、肝脏、脾脏和中枢神经系统等髓外部位。由于骨髓置换和正常血细胞生成受损,会导致疲劳、苍白、发热、出血或瘀伤、淋巴结肿大以及骨痛等临床表现。如果不及时治疗,ALL 会迅速进展,并可能导致危及生命的并发症,例如感染、出血、器官衰竭和死亡。 T 细胞急性淋巴细胞白血病 (T-ALL) 是一种涉及 T 细胞前体恶性转化的亚型,表现出类似的侵袭性特征和全身性受累。

Acute Lymphoblastic Leukemia (ALL) is an aggressive hematologic malignancy characterized by the rapid proliferation of immature lymphoid cells (lymphoblasts) in the bone marrow and peripheral blood, leading to suppression of normal hematopoiesis. It primarily affects children but can also occur in adults, with a higher incidence in young individuals. The disease involves the uncontrolled growth of abnormal lymphocytes that infiltrate the bone marrow, peripheral blood, and often spread to extramedullary sites such as lymph nodes, liver, spleen, and central nervous system. This results in clinical manifestations including fatigue, pallor, fever, bleeding or bruising, lymphadenopathy, and bone pain due to bone marrow replacement and impaired production of normal blood cells. Without prompt treatment, ALL progresses rapidly and can lead to life-threatening complications such as infection, hemorrhage, organ failure, and death. T-cell acute lymphoblastic leukemia (T-ALL) is a subtype involving malignant transformation of T-cell precursors, exhibiting similar aggressive features and systemic involvement.

Acute Lymphoblastic Leukemia (5):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-164466A
    CAD204520 dihydrochloride 2682205-21-4 99.26%
    CAD204520 dihydrochloride 是一种 SERCA 的抑制剂 (IC50 = 0.34 μM),靶向 T 细胞急性淋巴细胞白血病 (T-ALL) 和套细胞淋巴瘤 (MCL) 中突变型 NOTCH1 蛋白。CAD204520 dihydrochloride 可用于 T-ALL 和 MCL 相关研究。
    CAD204520 dihydrochloride
  • HY-120120
    DZ-2384 1403850-91-8
    DZ-2384 是一种强效的微管 (microtubule) 靶向剂。DZ-2384可提高微管救援频率,并在非分裂细胞和原代神经元中保持微管网络结构。在 Taxane 敏感和 Taxane 耐药的三阴性乳腺癌 (TNBC) 异种移植小鼠模型中,DZ-2384 与抗 CTLA-4 联用具有协同作用。DZ-2384 在成人急性淋巴细胞白血病 (ALL) 模型中表现出强大的抗肿瘤活性。DZ-2384 可用于癌症研究,例如 TNBC 和 ALL[1][2]
    DZ-2384
  • HY-179242
    RIPK1-IN-37-CO-Ph-alkynyl-Py-Pip
    RIPK1-IN-37-CO-Ph-alkynyl-Py-Pip 是一种配体-连接体,靶向 RIPK1。RIPK1-IN-37-CO-Ph-alkynyl-Py-Pip 可用于合成 PROTAC LD5097 (HY-179234)。
    RIPK1-IN-37-CO-Ph-alkynyl-Py-Pip
  • HY-179235
    RIPK1-IN-37 2782024-39-7
    RIPK1-IN-37 是一种 RIPK1 抑制剂,也是 PROTAC (LD5097) 靶蛋白的配体。RIPK1-IN-37 可用于合成 PROTAC LD5097 (HY-179234)。
    RIPK1-IN-37
  • HY-179234
    LD5097
    LD5097 是一种高效且选择性的 PROTAC 降解剂,靶向 RIPK1。LD5097 可快速有效地下调 RIPK1,并显著增强 Jurkat 细胞中 TNFα 介导的细胞凋亡 (apoptosis)。LD5097 可显著提高裂解型 caspase-3/7PARP 的水平。LD5097 可用于急性 T 淋巴细胞白血病的研究。
    LD5097